Skip to content
Catalyst

PapersPMID:31398841

Metabolic Effects of Resistant Starch Type 2: A Systematic Literature Review and Meta-Analysis of Randomized Controlled Trials.

Nutrients2019The record ↗

findings
5
compound
1
endpoints
5
PMID:31398841
  1. Finding, strong evidenceno difference foundLDL cholesterol
  2. Finding, strong evidenceno difference foundHDL cholesterol
  3. Finding, strong evidenceno difference foundFasting blood glucose
  4. Finding, strong evidenceno difference foundGlycated haemoglobin (HbA1c)
  5. Finding, strong evidenceno difference foundTotal cholesterol (TC)
Study, every finding
meta-analysis
Dose studied, every finding
8 to 66 g RS2 per day across trials

No finding here moved its endpoint.

  • “A meta-analysis of all seven studies (n = 406) indicated no significant reduction in LDL cholesterol levels following RS2 supplementation (MD = 0.03 mmol/L; 95% CI −0.10, 0.16, P = 0.66).”
    Participants
    406
    Effect
    0.03 mean difference, 95% CI −0.1 to 0.16
    Population
    Healthy individuals and people with the metabolic syndrome or type 2 diabetes, pooled across seven randomized trials
  • “A meta-analysis of all ten studies (n = 532) indicated no significant change in HDL cholesterol levels following RS2 supplementation in healthy people, those with MetS or individuals with T2DM (MD = −0.01 mmol/L; 95% CI −0.07, 0.04, P = 0.67).”
    Participants
    532
    Effect
    −0.01 mean difference, 95% CI −0.07 to 0.04
    Population
    Healthy people and people with the metabolic syndrome or type 2 diabetes, pooled across ten randomized trials
  • “A meta-analysis of all fifteen studies (n = 636) indicated no statistically significant changes in fasting plasma glucose following RS2 supplementation in healthy subjects, subjects with MetS, and subjects with T2DM (MD = −0.03 mmol/L; 95% CI −0.11, 0.05, P = 0.40).”
    Participants
    636
    Effect
    −0.03 mean difference, 95% CI −0.11 to 0.05
    Population
    Healthy subjects, subjects with the metabolic syndrome (MetS) and subjects with type 2 diabetes, pooled across fifteen randomized trials
  • “Despite significant reductions in HbA1c observed in two studies undertaken by the same research group, a meta-analysis of all five studies (n = 265) indicated no statistically significant effects of RS2 supplementation on HbA1c in trial participants with prediabetes or T2DM (MD = −0.27%; 95% CI −0.57, 0.03, P = 0.08).”
    Participants
    265
    Effect
    −0.27 mean difference, 95% CI −0.57 to 0.03
    Population
    Participants with prediabetes or type 2 diabetes, pooled across five randomized trials
  • “A meta-analysis of all twelve studies (n = 634) investigating the effect of RS2 supplementation on total cholesterol in healthy individuals and those with MetS or T2DM indicated no significant change in total cholesterol (MD = −0.06 mmol/L; 95% CI: −0.15, 0.03, P = 0.18).”
    Participants
    634
    Effect
    −0.06 mean difference, 95% CI −0.15 to 0.03
    Population
    Healthy individuals and people with the metabolic syndrome or type 2 diabetes, pooled across twelve randomized trials

Study record

Design
meta-analysis
Species
human
Population
Healthy, overweight/obese, metabolic syndrome, prediabetic and type 2 diabetic adults (22 RCTs, 670 participants, aged 23 to 70); resistant starch type 2 at 8 to 66 g/day for 1 to 12 weeks against placebo or control, mostly from high amylose maize starch, one trial native banana starch and one potato starch
Participants
670
Comparator
placebo
Duration
not reported
Endpoints measured
23